Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoV2 preS dTM + AF03
- Development stage
- Discontinued
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CoV2 preS dTM + AF03 is a recombinant protein subunit vaccine candidate developed by Sanofi for the prevention of COVID-19. The vaccine consists of a stabilized, soluble version of the SARS-CoV-2 spike protein (preS dTM), which has been modified by deleting the transmembrane domain and using a pre-fusion stabilized conformation. This antigen is produced using Sanofi's proprietary baculovirus expression system. The formulation is adjuvanted with AF03, a squalene-based oil-in-water emulsion developed by Sanofi to enhance the immune response. During early clinical development (Phase 1/2), this formulation was evaluated alongside an AS03-adjuvanted version (developed in partnership with GSK). While the AS03-adjuvanted version (VidPrevtyn) proceeded to Phase 3 trials and regulatory approval, the AF03-adjuvanted version was not pursued for further late-stage development.
- Other names
- Sanofi COVID-19 recombinant protein vaccine (AF03)SARS-CoV-2 recombinant protein vaccine + AF03CoV2 preS dTM-AF03CoV-2 preS dTM-AF03CoV 2 preS dTM-AF03
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on CoV2 preS dTM + AF03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoV2 preS dTM + AF03.